Bioresources

School of Biological Sciences

Research Papers Published

• "Inflammatory Mechanisms as Potential Therapeutic Targets in Stroke" Advances in Neuroimmune Biology, 5(1): 199 -216 {ISSN: 1878-9498} Impact Factor=
• "Effect of Supine Versus Semi-Fowler’s Position on Hemodynamic stability of patients with Head injury" World Journal of Pharmaceutical Research, 4(4): 121 -130 {ISSN: 2277-7105} Impact Factor=
• "123I-FP-CIT SPECT imaging in early diagnosis of dementia in patients with and without a vascular component" Frontiers in System Neurosciences, 9(99): 1 -11 {ISSN: 1662-5137} Impact Factor=
• "Immunomodulation of Inflammatory Markers in Activated Macrophages by Leaf Extracts of Gingko Biloba" Advances in Neuroimmune Biology, 5(5): 127 -139 {ISSN: 1878-9498} Impact Factor=
• "TNF Receptor Modulation by Gentiana Extracts Acts as Neuroprotective Mechanism in Stroke by Enhancing Cellular Survival." Stroke, 45(12): e259 -298 {ISSN: 1524-4628} Impact Factor=
• "Immunomodulation of Inflammatory Markers in Activated Macrophages by Leaf Extracts of Gingko Biloba" Advances in Neuroimmune Biology, 6(1): 9 -17 {ISSN: 1878-9498} Impact Factor=
• "BAD a Proapoptotic Protein Escapes ERK RSK Phosphorylation in Deguelin and siRNA Treated HeLa Cells" Plos One, 11(1): Pub Med ID. PMC4706341 {ISSN: 19326203} Impact Factor= 3.3
• "Impact of co-signaling on the survival of intracellular pathogens in macrophages" International Journal of Advance Research in Science and Engineering, 7(4): 3166 -3183 {ISSN: 2319-8354} Impact Factor=
• "Double-Crosser of the Immune System: Macrophages in tumor progression and metastasis" Current Immunological Reviews, 15(2): DOI No. 10.2174/1573395515666190611122 {ISSN: 1875-631X} Impact Factor= 0.657
• "Recent advances in metabolites from medicinal plants in cancer prevention and treatment" Current Immunological, 15(2): DOI No. 10.2174/1573395515666191102094 {ISSN: 1875-631X} Impact Factor= 0.657
• "Nanobodies: the magic bullets in therapeutics, drug delivery and diagnostics" Human Antibodies, 21(1): DOI No. 10.3233/HAB-190390 {ISSN: 1875-869X} Impact Factor= 0.456
• "Recent Advances in Chemotherapeutic Implications of Deguelin, A Plant Derived Retinoid" The Natural Products Journal, 11(2): DOI No. 10.2174/2210315510666200128125 {ISSN: 2210-3163} Impact Factor= 0.856
• "Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer" Current Cancer Drug Targets, 20(8): DOI No. 10.2174/1570163817666200518081 {ISSN: 1873-5576} Impact Factor= 3.324
• "Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis" Current Pharmaceutical Biotechnology, 22(4): DOI No. 10.2174/1389201021666200628021 {ISSN: 1873-4316} Impact Factor= 2.354
• "Rising trends of Cancers in Kashmir valley: Distribution Pattern, Incidence and Causes" Journal of Oncology Research and Treatment, 5(2): 150 -163 Impact Factor= 078
• "Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes" Current Drug Targets, 22(17): DOI No. 10.2174/1389450121666201228123 {ISSN: 1873-5592} Impact Factor= 2.868
• "Tumor microenvironment promotes breast cancer chemoresistance" Cancer Chemotherapy and Pharmacology, 87(2): DOI No. 10.1007/s00280-020-04222-w {ISSN: 1432-0843} Impact Factor= 2.967
• "Glucose - The X factor for the survival of human fungal pathogens and disease progression in the host" Microbial Research, 247(6): DOI No. 10.1016/j.micres.2021.126725 {ISSN: 2036-7481} Impact Factor= 3.978
• "Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives" Breast Cancer, 28(3): DOI No. 10.1007/s12282-021-01231-2 {ISSN: 1880-4233} Impact Factor= 2.695
• "Recent Advances in Chemotherapeutic Implications of Deguelin: A Plant-Derived Retinoid" The Natural Products Journal, 11(2): DOI No. 10.2174/2210315510666200128125 {ISSN: 2210-3163} Impact Factor=
• "Comparative Study on Phytochemical Profile and Antioxidant Activity of an Epiphyte, Viscum album L. (White Berry Mistletoe), Derived from Different Host Trees" Plants, 10(6): DOI No. 10.3390/plants10061191 {ISSN: 2223-7747} Impact Factor= 3.935
• "Glucose - The X factor for the survival of human fungal pathogens and disease progression in the host" Microbiological Research, 247(6): DOI No. 10.1016/j.micres.2021.126725 {ISSN: 0944-5013} Impact Factor= 5.415
• "Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives" Breast Cancer, 28(5): DOI No. 10.1007/s12282-021-01231-2 {ISSN: 1880-4233} Impact Factor= 4.234
• "Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis" Current Pharmaceutical Biotechnology, 22(4): DOI No. 10.2174/1389201021666200628021 {ISSN: 1873-4316} Impact Factor= 2.987
• "Tumor microenvironment promotes breast cancer chemoresistance" Cancer Chemotherapy and Pharmacology, 87(2): DOI No. 10.1007/s00280-020-04222-w {ISSN: 1432-0843} Impact Factor= 3.333
• "The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities" Cellular Oncology, 44(5): DOI No. 10.1007/s13402-021-00634-9 {ISSN: 22113428} Impact Factor= 6.730
• "An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer" Future Oncology, 17(31): DOI No. 10.2217/fon-2021-0172 {ISSN: 1744-8301} Impact Factor= 3.404
• "Strategies employed to evade the host immune response and the mechanism of drug resistance in Mycobacterium tuberculosis: In search of finding new targets" Current Pharmaceutical Biotechnology, 22(17): DOI No. 10.2174/1389201023666211222164 {ISSN: 1873-4316} Impact Factor= 2.987
• "Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis" Journal of Biomedical Nanotechnology, 17(12): DOI No. 10.1166/jbn.2021.3201 {ISSN: 1550-7041} Impact Factor= 4.483
• "In vitro and in silico evaluation of antimicrobial properties of Delphinium cashmerianum L., a medicinal herb growing in Kashmir, India" Journal of Ethnopharmacology, 291(6): DOI No. 10.1016/j.jep.2022.115046 {ISSN: 0378-8741} Impact Factor= 4.360
• "Expression pattern and prognostic significance of baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) in breast cancer: A comprehensive analysis" Advances in Cancer Biology - Metastasis, 4(7): DOI No. 10.1016/j.adcanc.2022.100037 {ISSN: 2667-3940} Impact Factor=
• "Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications" Seminars in Cancer Biology, 80(3): DOI No. 10.1016/j.semcancer.2022.03.00 {ISSN: 1044-579X} Impact Factor= 15.707
• "Metformin treatment ameliorates endocrine-metabolic disturbances in letrozole-induced PCOS mice model by modulating adiponectin status" Obesity Medicine, 31(5): DOI No. 10.1016/j.obmed.2022.100392 {ISSN: 2451-8476} Impact Factor= 1.5
• "Chemokines in triple- negative breast cancer heterogeneity: New challenges for clinical implications" Seminars in Cancer Biology, 84(3): DOI No. 1 {ISSN: 1044-579X} Impact Factor= 17.012
• "Adapalene and doxorubicin synergistically promote apoptosis of TNBC Cells by hyperactivation of the ERK1/2 pathway through ROS induction" Frontiers in Oncology, 12(6): DOI No. 10.338 {ISSN: 2234-943X} Impact Factor= 6.244
• "Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC- 0941" Frontiers in Pharmacology, 13(7): DOI No. 10.3389/ {ISSN: 1663-9812} Impact Factor= 5.988
• "Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study" Medical Oncology, 39(10): DOI No. 10.1007/s12032-022-01779-9 {ISSN: 1559131X} Impact Factor= 3.738
• "Expression Pattern and Prognostic Significance of Chemokines in Breast cancer: An Integrated Bioinformatics Analysis" Clinical Breast Cancer, 22(5): DOI No. 10.1016/j. clbc.2022.04.008 {ISSN: 1526-8209} Impact Factor= 3.225
• "Cryptolepine Targets TOP2A and Inhibits Tumor Cell Proliferation in Breast Cancer Cells - An in vitro and in silico Study" Anti-Cancer Agents in Medicinal Chemistry, 22(3): DOI No. 10.2174/1871520622666220419135 {ISSN: 18755992} Impact Factor= 2.680
• "Expression Pattern and Prognostic significance of CDKs in Breast Cancer: An Integrated Bioinformatic Study." Cancer Biomarkers, 34(3): DOI No. 10.3233/CBM-210186 {ISSN: 505-519} Impact Factor= 4.333
• "Cyclin-Dependent Kinases in Breast Cancer: Expression Pattern and Therapeutic Implications" Medical Oncology, 34(6): DOI No. 10.1007/s12032-022-01731-x {ISSN: 1559131X} Impact Factor= 3.738
• "antimicrobial properties of Delphinium cashmerianum L., a medicinal herb growing in Kashmir, India." Journal of Ethnopharmacology, 297(6): DOI No. 10.1016/j.jep.2022.115046 {ISSN: 0378-8741} Impact Factor= 5.107
• "Natural therapeutics in aid of treating Alzheimer’s disease (AD): A green gateway towards ending the quest for treating neurological disorders" Frontiers in Neuroscience, 16(6): DOI No. 10.3389/fnins.2022.884345 {ISSN: 1662-453X} Impact Factor= 4.501
• "Quinidine Drug Resistance transporter Knockout Candida cells modulate glucose transporter expression and accumulate metabolites leading to enhanced azole drug resistance" Fungal Genetics and Biology, 161(7): DOI No. 10.1016/j.fgb. {ISSN: 10871845} Impact Factor= 3.883
• "Targeting Cyclin-dependent kinase 1 (CDK1) in Cancer: Molecular Docking and Dynamic Simulations of potential CDK1 Inhibitors" Medical Oncology, 39(4): DOI No. 10.1007/s {ISSN: 1559131X} Impact Factor= 3.738
• "Strategies employed to evade the host immune response and the mechanism of drug resistance in Mycobacterium tuberculosis: In search of finding new targets" Current Pharmaceutical Biotechnology, 23(1): DOI No. 10.2174/1389201023666211222164 {ISSN: 1873-4316} Impact Factor= 2.840
• "Evaluation of the In Vitro Antimicrobial Activities of Delphinium roylei: An Insight from Molecular Docking and MD-Simulation Studies" Medicinal Chemistry, 18(4): DOI No. 10.2174/1573406418666220429093 {ISSN: 1875-6638} Impact Factor= 2.329
• "Manipulation and exploitation of host immune system by pathogenic Mycobacterium tuberculosis for its advantage" Future Microbiology, 17(8): DOI No. 10.2217/fmb-20 {ISSN: 1746-0913} Impact Factor= 3.553
• "Natural products and their semi-synthetic derivatives against antimicrobial-resistant human pathogenic bacteria and fungi" Saudi Journal of Biological Sciences, 29(9): DOI No. 10.1016/j.sjbs {ISSN: 1319-562X} Impact Factor= 4.052
• "Molecular docking analysis and evaluation of the antimicrobial properties of the constituents of Geranium wallichianum D. Don ex Sweet from Kashmir Himalaya" Scientific Reports (Springer-Nature), 12(7): DOI No. 10.1038/s41598-022-16102-9 {ISSN: 2045-2322} Impact Factor= 4.996
• "Metabolite fingerprinting of phytoconstituents from Fritillaria cirrhosa D. Don and molecular docking analysis of bioactive peonidin with microbial drug target proteins." Scientific Reports (Nature Springer), 12(5): DOI No. 10.1038/s 4159 {ISSN: 245-2322} Impact Factor= 4.996
• "Expression pattern and prognostic significance of baculoviral inhibitor of apoptosis repeat- containing 5 (BIRC5) in breast cancer: A comprehensive analysis." Advances in Cancer Biology-Metastasis, 4(3): DOI No. 10.1016/j. adc {ISSN: 2667-3940} Impact Factor= 0.0
• "Metformin treatment ameliorates endocrine metabolic disturbances in the letrozole-induced PCOS mice model by modulating adiponectin Status" Obesity Medicine, 31(5): DOI No. 10.1016/j.obme {ISSN: 24518476} Impact Factor= 0.00
• "A Novel Prognostic Biomarker with Potential of High Diagnostic Accuracy in Pulmonary Tuberculosis: An in silico Study" International Journal of Pharmaceutical Investigation, 12(2): DOI No. 10.5530/ijpi.2 {ISSN: 2230-9713} Impact Factor= 0.00
• "Chlorogenic acid restores ovarian functions in mice with letrozole-induced polycystic ovarian syndrome via modulation of adiponectin receptor" Biomedicines, 11(3): DOI No. 10.3390/biomedicines11030900 {ISSN: 2227-9059} Impact Factor= 4.757
• "Ginger extract ameliorates endocrine-metabolic disturbances in letrozoleinduced PCOS mice model by altering androgen-adiponectin status" Obesity Medicine, 39(3): DOI No. 10.1016/j.obmed.2023.100485 {ISSN: 2451-8476} Impact Factor= 1.323
• "Synthesis and Biological Evaluation of Novel Uracil Derivatives as Thymidylate Synthase Inhibitors" Applied Biochemistry and Biotechnology, 195(2): DOI No. 10.1007/s12010-023-04367-3 {ISSN: 2732289} Impact Factor= 3.094
• "Immunomodulatory efficacy of Cousinia thomsonii C.B. Clarke in ameliorating inflammatory cascade expressions" Journal of Ethnopharmacology, 300(1): DOI No. 10.1016/j.jep.2022.115727 {ISSN: 1872-7573} Impact Factor= 5.195
• "A systematic review on the safety and eìcacy of COVID-19 vaccines approved in Saudi Arabia" Vaccines, 11(2): DOI No. 10.3390/vaccines11020281 {ISSN: 2076-393X} Impact Factor= 4.961
• "Identiêcation and analysis of dysregulated fatty acid metabolism genes in breast cancer subtypes" Medical Oncology, 39(10): DOI No. 10.1007/s12032-022-01861-2 {ISSN: 1559131X} Impact Factor= 3.738
• "Molecular Prediction and Correlation of the Structure and Function of Universal Stress Protein A (UspA) from Salmonella Typhimurium" Biochemical Genetics, 62(2): DOI No. 10.1007/s10528-024-10699-4 {ISSN: 1573-4927} Impact Factor= 2.4
• "Transcription Factors-Golden Keys to Modulate the Plant Metabolism to Develop Salinity Tolerance" Plant Stress, 11(3): DOI No. 10.1016/j.stress.2024.100409 {ISSN: 2667-064X} Impact Factor= 5.4
• "Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology" Heliyon, 10(7): DOI No. 10.1016/j.heliyon.2024.e24670 {ISSN: 2405-8440} Impact Factor= 4.2
• "Targeting p53 misfolding conundrum by stabilizing agents and their analogs in breast cancer therapy: a comprehensive computational analysis" Frontiers in Pharmacology, 10(14): DOI No. 10.3389/fphar.2023.1333447 {ISSN: 1663-9812} Impact Factor= 5.828
• "Deciphering the chemical constituents and antimicrobial activity of Prangos pabularia Lindl. using LC-MS/MS in combination with experimental evaluation and computational studies" Natural Product Chemistry, 38(2): DOI No. 10.1080/14786419.2023.2300394 {ISSN: 1478-6427} Impact Factor= 2.488
• "Clinicopathological Significance and Expression Pattern of Bcl2 in Breast Cancer: A Comprehensive in silico and in vitro Study" Saudi Journal of Biological Sciences, 31(2): DOI No. 10.1016/j.sjbs.2023.103916 {ISSN: 1319-562X} Impact Factor= 4.465
• "Network pharmacology and experimental validation for deciphering the action mechanism of Fritillaria cirrhosa D. Don constituents in suppressing breast carcinoma" Journal of Biomolecular Structure and Dynamics, 41(20): DOI No. 10.1080/07391102.2023.2274966 {ISSN: 1538-0254} Impact Factor= 5.678
• "Administration of metformin ameliorates endocrine abnormalities associated with mouse model of PCOS by increasing Cyp19a1 expression" Comparative Clinical Pathology, 33(4): DOI No. 10.1007/s00580-023-03534-6 {ISSN: 1618-565X} Impact Factor= 0.97
• "Decoding the molecular mechanism of stypoldione against breast cancer through network pharmacology and experimental validation" Saudi Journal of Biological Sciences, 30(12): DOI No. 10.1016/j.sjbs.2023.103848 {ISSN: 1319-562X} Impact Factor= 4.465
• "Targeting Breast Cancer Stem Cells through Retinoids: A New Hope for Treatment" Critical Reviews in Oncology/Hematology, 192(12): DOI No. 10.1016/j.critrevonc.2023.1041 {ISSN: 1040-8428} Impact Factor= 6.256
• "Network pharmacology combined with molecular docking and in vitro verification reveals the therapeutic potential of Delphinium roylei munz constituents on breast carcinoma" Frontiers in Pharmacology, 14(8): DOI No. 10.3389/fphar.2023.1135898 {ISSN: 1663-9812} Impact Factor= 5.828
• "Integrons in the Development of Antimicrobial Resistance: Critical Review and Perspectives" Frontiers in Microbiology, 14(8): DOI No. 10.3389/fmicb.2023.1231938 {ISSN: 1664-302X} Impact Factor= 5.289
• "Elucidation of Interleukin-19 as a therapeutic target for breast cancer by computational analysis and experimental validation" Saudi Journal of Biological Sciences, 30(9): DOI No. 10.1016/j.sjbs.2023.103774 {ISSN: 1319-562X} Impact Factor= 4.465
• "A network pharmacology-based investigation of brugine reveals its multi-target molecular mechanism against Breast Cancer" Medical Oncology, 40(6): DOI No. 10.1007/s12032-023-02067-w {ISSN: 1559-131X} Impact Factor= 3.4
• "Mechanistic elucidation of Juglanthraquinone C targeting breast Cancer: A network Pharmacology-based investigation" Saudi Journal of Biological Sciences, 30(7): DOI No. 10.1016/j.sjbs.2023.103705 {ISSN: 1319-562X} Impact Factor= 4.465
• "A comprehensive analysis of notch signalling genes in breast cancer: Expression pattern and prognostic significance" Advances in Cancer Biology - Metastasis, 7(7): DOI No. 10.1016/j.adcanc.2023.100104 {ISSN: 2667-3940} Impact Factor= 0.845
• "Physicochemical and Anti-fungal Studies of the Pharmaceutical Co-crystal/Salt of Fluconazole" Molecular Pharmaceutics, 20(7): DOI No. 10.1021/acs.molpharmaceut.3c00 {ISSN: 1543-8392} Impact Factor= 5.678
• "Immunotherapies against human bacterial and fungal infectious diseases" Frontiers in Medicine, 10(4): DOI No. 10.3389/fmed.2023.1135541 {ISSN: 2296-858X} Impact Factor= 3.985
• "Effect of quercetin on steroidogenesis and folliculogenesis in ovary of mice with experimentally-induced polycystic ovarian syndrome" Frontiers in Endocrinology, 14(4): DOI No. 10.3389/fendo.2023.1153289 {ISSN: 1664-2392} Impact Factor= 5.286
• "Role of diacerein on steroidogenesis and folliculogenesis related genes in ovary of letrozole-induced PCOS mice" Chemico Biological Interactions, 377(4): DOI No. 10.1016/j.cbi.2023.110468 {ISSN: 1872-7786} Impact Factor= 5.192
• "Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis" Immunologic Research, 71(4): DOI No. 10.1007/s12026-023-09376-2 {ISSN: 1559-0755} Impact Factor= 4.487
• "Chlorogenic Acid Restores Ovarian Functions in Mice with Letrozole-Induced Polycystic Ovarian Syndrome Via Modulation of Adiponectin Receptor" Biomedicines, 11(3): DOI No. 10.3390/biomedicines11030900 {ISSN: 2227-9059} Impact Factor= 4.758
• "Ginger extract ameliorates endocrine-metabolic disturbances in letrozole-induced PCOS mice model by altering androgen- adiponectin status" Obesity Medicine, 39(5): DOI No. 10.1016/j.obmed.2023.100485 {ISSN: 2451-8476} Impact Factor= 2.456

Books Published

• "Introduction to Costimulation and Costimulatory Molecules". Elsevier Publishers USA. {ISBN: 978-0-12-80-2585-7} pp 44
• "Concept of Reverse Costimulation and Its Role in Diseases". Elsevier Publishers USA. {ISBN: 978-0-12-80-2585-7} pp 37
• "Costimulation Immunotherapy in Infectious Diseases". Elsevier Publishers USA. {ISBN: 978-0-12-80-2585-7} pp 45
• "Costimulation Immunotherapy in Allergies and Asthma". Elsevier Publishers USA. {ISBN: 978-0-12-80-2585-7} pp 47
• "Costimulation in Lymphomas and Cancers". Elsevier Publishers USA. {ISBN: 978-0-12-80-2585-7} pp 69
• "T-Cell Costimulation and Its Applications in Diseases". Elsevier Publishers USA. {ISBN: 978-0-12-80-2585-7} pp 38
• "Role of Natural Herbs in Stroke Prevention and Treatment". Nova Science Biomedical Publishers USA. {ISBN: 978-1-63483-555-8} pp 264
• "An Introduction to Cerebrovascular Diseases". Nova Science Publishers New York USA. {ISBN: 978-1-63483-555-8} pp 51
• "Immunobiology of Stroke". Nova Science Publishers New York USA. {ISBN: 978-1-63483-555-8} pp 61
• "Natural Herbs, Human Brain and Neuroprotection". Nova Science Publishers New York USA. pp 62
• "Natural Herbs in Stroke prevention and Treatment". Nova Science Publishers New York USA. pp 36
• "Polyphenols from Natural Herbs in Neuroprotection". Nova Science Publishers New York USA. pp 47
• "Role of Natural Herbs in Prevention and Treatment of Stroke". Nova Science Publishers New York USA. {ISBN: 978-1-63483-574-9} pp 310
• "Basics and Fundamentals of Immunology". Nova Science Publishers USA. {ISBN: 978-1-53616-639-2} pp 334
• "Immunoglobulins, Magic Bullets and Therapeutic Antibodies". Biomedical NOVA Science Publishers Newyork USA. {ISBN: 978-1-53616-903-4} pp 365
• "Cytokines and their Therapeutic potential". Nova Science Publishers Newyork USA. {ISBN: 978-1-53617-017-7} pp 285
• "The fundamentals of Hypersensitivities and Allergies". Nova Biomedical Science Publishers New York USA. {ISBN: 978-1-53617-012-2} pp 184
• "Plant Metabolites in the Treatment of Cancer and cerebrovascular Diseases". OMICS Science International Publishers USA. {ISBN: 978-1-63278-073-7} pp 176
• "Natural Medicine in Cerebrovascular Diseases". Ariana Publishers New Delhi India. {ISBN: 9789385497940} pp 127
• "Nanomedicine in Human Health Therapeutics and Drug Delivery/Applications of Nanomaterials in Agriculture, Food Science, and Medicine". IGI Global Publishers. {ISBN: 9781799855644} pp 23
• "Combination Therapies and their Effectiveness in Breast Cancer Treatment". NOVA Biomedical Science Publishers USA. {ISBN: 978-1-68507-195-0} pp 345
• "Integrating Immunotherapy with Targeted Therapies and Chemotherapy: A New Paradigm in TNBC Treatment". Intech Open International Publishers UK. {ISBN: 978-1-83969-958-0} pp 46
• "Role of immunogenetics polymorphisms in infectious diseases". Elsevier Publishers USA. {ISBN: 978-0-323-90053-9} pp 56
• "Antioxidants (Natural and Synthetic) Screening Assays: An Overview". Bentham Science Publishers. {ISBN: 978-981-4998-88-8} pp 22
• "Antioxidants in Cancer Prevention and Combination Therapy". Bentham Science Publishers. {ISBN: 978-981-4998-88-8} pp 18
• "Immuno-onco-metabolism and Therapeutic Resistance". Springer Nature. {ISBN: 978-9811662256} pp 36
• "Combinational Therapy in Triple Negative Breast Cancer". Elsevier Sciences USA. {ISBN: 9780323961363} pp 368
• "Human Pathogenic Microbes: Diseases and Concerns". Elsevier Sciences USA. {ISBN: 9780323961271} pp 412
• "Chapter 1 - Human pathogenic microbes (bacterial and fungal) and associated diseases". Elsevier. {ISBN: 978-0-323-96127-1} pp 30
• "Chapter 2 - Evolution of antimicrobial drug resistance in human pathogenic bacteria". Elsevier. {ISBN: 978-0-323-96127-1} pp 22
• "Chapter 3 - Evolution of antimicrobial drug resistance in human pathogenic fungi". Elsevier. {ISBN: 978-0-323-96127-1} pp 18
• "Chapter 4 - Combating human bacterial infections: need for new antibacterial drugs and therapeutics". Elsevier. {ISBN: 978-0-323-96127-1} pp 31
• "Chapter 5 - Combating human fungal infections: need for new antifungal drugs and therapies". Elsevier. {ISBN: 978-0-323-96127-1} pp 25
• "Chapter 6 - Significance of immunotherapy for human bacterial diseases and antibacterial drug discovery". Elsevier. {ISBN: 978-0-323-96127-1} pp 32
• "Chapter 7 - Significance of immunotherapy for human fungal diseases and antifungal drug discovery". Elsevier. {ISBN: 978-0-323-96127-1} pp 23
• "Chapter 8 - Combinatorial approach to combat drug resistance in human pathogenic bacteria". Elsevier. {ISBN: 978-0-323-96127-1} pp 20
• "Chapter 9 - Combinatorial approach to combat drug resistance in human pathogenic fungi". Elsevier. {ISBN: 978-0-323-96127-1} pp 16
• "Chapter 10 - Recent trends in the development of bacterial and fungal vaccines". Elsevier. {ISBN: 978-0-323-96127-1} pp 27
• "Human pathogenic microbes: diseases and concerns". Elsevier USA. {ISBN: 9780323961271} pp 432
• "Combinational Therapy in Triple Negative Breast Cancer". Elsevier USA. {ISBN: 9780323961363} pp 386
• "Role of tumor microenvironment in breast cancer and targeted Therapies". Elsevier USA. {ISBN: 9780443186967} pp 297
• "Therapeutic potential of Cell Cycle Kinases in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 373
• "Proteomics: A groundbreaking development in cancer biology". Springer Nature. {ISBN: 978-0-323-95072-5} pp 23
• "Proteomics: Application of next-generation proteomics in cancer research". Springer Nature. {ISBN: 978-0-323-95072-5} pp 24
• "Introduction to Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 22
• "Current Treatment Approaches to Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 29
• "Introduction to Cell Cycle and Its Regulators". Springer Nature. {ISBN: 978-981-19-8911-7} pp 30
• "Cell Cycle and Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 19
• "Cell Cycle Dysregulation in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 29
• "Breast Tumor Microenvironment and CDKs". Springer Nature. {ISBN: 978-981-19-8911-7} pp 26
• "CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis". Springer Nature. {ISBN: 978-981-19-8911-7} pp 20
• "CDK1 Dysregulation in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 16
• "Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers". Springer Nature. {ISBN: 978-981-19-8911-7} pp 22
• "Therapeutic Implications of CDKs in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 20
• "Novel CDK Inhibitors in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 16
• "Targeting CDKs with Other Chemotherapeutic Drugs: A Combinatorial Approach". Springer Nature. {ISBN: 978-981-19-8911-7} pp 21
• "CDKs in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 21
• "CDk Inhibitor for Treatment of Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 21
• "Response of Therapy in Cell-Cycle Regulatory Genes in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 19
• "Different Cyclins and Their Significance in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 19

Research Projects Details:

Research Scholars: